Towards Healthcare
Clinical Genomics Market Soars at 17.54% CAGR by 2034

Clinical Genomics Market Growth and Opportunities

Projections indicate that, the global clinical genomics market will increase from USD 1.06 billion in 2024 to USD 5.34 billion by 2034, experiencing a CAGR of 17.54% over the next 10 years. The clinical genomics market is expanding due to growing occurrences of genetic and rare diseases as well as rising advancements in molecular diagnostic testing. North America led the market due to the presence of the advanced healthcare sector. 

Content

  • Insight Code: 5754
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The market is growing at a CAGR of 17.54% (2025–2034), driven by rising cases of genetic and rare diseases, rapid advancements in molecular diagnostics (like NGS and CRISPR), and increasing integration of AI in personalized and precision medicine

With the market projected to grow from US$ 1.25 billion in 2025 to US$ 5.34 billion by 2034, the sector presents a strong investment case.

AI is transforming clinical genomics by enabling rapid genomic data interpretation, enhancing phenotype predictions, improving precision in drug discovery, and personalizing treatment pathways

Asia Pacific is expected to be the fastest-growing region due to expanding healthcare infrastructure, increasing R&D investments, and rising awareness of genetic diseases.

Next-generation sequencing (NGS), liquid biopsy, CRISPR-based diagnostics, and AI-integrated analysis platforms are key trends.

High costs, complex data interpretation, limited reimbursement models, and a shortage of skilled professionals are key challenges.

Collaborations-such as Illumina & Nashville Biosciences AGD initiative and GenePoweRx AI alliances—are pivotal.

While stringent, evolving regulations are ensuring high accuracy and patient safety, they can delay product launches and increase operational costs.

Leaders include Illumina, Quest Diagnostics, PerkinElmer, Invitae, Myriad Genetics, Natera, and Eurofins.

The future is bright with increasing adoption in routine clinical settings, advancements in personalized therapies, and growing public-private funding.
Any Questions